



Delivered by Hand

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Zeldis

Confirmation No.: 1860

Serial No.: 10/699,105

Art Unit: 1641

Filed: October 30, 2003

Examiner: To be assigned

For: METHODS FOR THE
TREATMENT, PREVENTION
AND MANAGEMENT OF
MACULAR DEGENERATION

Attorney Docket No: 9516-073-999
(CAM No.: 501872-999072)

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.56 and 1.97

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §§ 1.56 and 1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing and prosecution of the above-identified application that are or may be related to patentability of the claimed invention, Attorneys for Applicants hereby invite the Examiner's attention to references **A01-A09, B01-B12 and C01-C38** which are listed on the accompanying Form PTO-1449 entitled "List of References Cited By Applicant."

A copy of references **A01-A09, B01-B12 and C01-C38** is submitted herewith. Identification of the listed references is not to be construed as an admission that such references are available as "prior art" against the subject application.

Applicants request that the Examiner review all the references identified on the attached Form PTO-1449, and that they be made of record in the file history of the above-identified application.

As this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits, Applicants estimate that no fee is required. Should a fee be required, please charge the required fee to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Anthony M. Insogna, Reg. No. 35,203
By: *Michael J. Bruner, Reg. No. 47,458*

Date November 11, 2004

By: Michael J. Bruner (Reg. No. 47,458)
For: Anthony M. Insogna (Reg. No. 35,203)

JONES DAY
222 East 41st Street
New York, New York 10017
(858) 314-1130



Delivered by Hand
Sheet 1 of 3

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO. 9516-073-999 (Cam.No. 501872-999072)	APPLICATION NO 10/699,105
	APPLICANT Jerome B. Zeldis	
	FILING DATE October 30, 2003	GROUP 1641

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
A01	3,095,415	6/25/63				
A02	3,522,263	7/28/70				
A03	3,541,110	11/17/70				
A04	4,879,252	11/07/89				
A05	5,985,867	11/16/99				
A06	6,114,333	9/05/00				
A07	6,361,760	11/26/02				
A08	6,555,539	4/29/03				
A09	US 2002/0161022	10/31/02				

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	YES	NO
B01	CS 146 895 1	11/12/71						
B02	DE 1266763	4/25/68						
B03	GB 1293557	9/04/70						
B04	GB 1404969	8/24/73						
B05	GB 1576217	7/22/77						
B06	GB 2003477	3/30/79						
B07	GB 1489280	10/19/77						
B08	GB 2345486	7/12/00						
B09	WO 01/12609	2/22/01						
B10	WO 02/10137	2/7/02						
B11	WO 02/46170	6/13/02						
B12	WO 89/10924	11/16/89						

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C01	Adam, J. et al., "Coagulation and Fibrinolysis in patients undergoing operation for ruptured and nonruptured infrarenal abdominal aortic aneurysms" Vascular Surgery, v. 30(4), pp. 641-650 (1999)
C02	Ames et al., "An integrated concept of amebicidal action: electron transfer and oxy radicals", Free Radical Biol. Med. 3:85-96 (1987)
C03	Andronati, Dopov. Akad. Nauk. Ukr., v. 8, pp. 126-131 (1994)
C04	Arya et al., "Synthesis of Nitroheterocycles: Part IV*-Synthesis of I-Substituted 4-Nitroisoquinolines, 5- & 6-Nitroindazoles & 6-Nitrobenzimidazoles" Indian J. Chem., Sect. B, v. 15B(7), pp. 625-628 (1977)
C05	Besson, JM., "The Neurobiology of Pain" Lancet 353:1610-1615 (1999)

	C06	Boehm et al., "Novel Inhibitors of DNA Gyrase: 3D Structure Based Biased Needle Screening, Hit Validation by Biophysical Methods, and 3D Guided Optimization. A Promising Alternative to Random Screening" <i>J. Med. Chem.</i> , v. 43(14), pp. 2664-2674 (2000)
	C07	Bruehl, et al., "External validation of IASP diagnostic criteria for Complex Regional Pain Syndrome and proposed research diagnostic criteria" <i>Pain</i> 81:147-154 (1999)
	C08	Buck, K., "Total Synthesis of Peruvianine, A Phenolic 7-oxoaporphine alkaloid of <i>Telitoxicum Peruvianum</i> " <i>Heterocycles</i> , v. 36(11), pp. 2489-2495 (1993)
	C09	Cervero, F. and Laird J., "Visceral pain" <i>Lancet</i> 353:2145-48 (1999)
	C10	Classification of Chronic Pain, International Association for the Study of Pain (IASP) Task Force on Taxonomy, Merskey H, Bogduk N. eds., IASP Press: Seattle, 209-214. (1994)
	C11	Dzwierzynski and Sanger., "Reflex Sympathetic Dystrophy" <i>Hand Clinics</i> Vol 10 (1):29-44 (1994)
	C12	Fujimura et al., "Synthesis and Pharmacological Activities of 2,3-Dihydro-1-H-pyrazolo-[1,2-a]indazolium Derivatives" v. 106(11), pp. 1002-1007 (1986)
	C13	Galushko and Dokunikhin, "Pyrazoloanthrone derivatives I. Reactivity of 3-aminopyrazoloanthrone", Khimiya Geterotsiklichesikh Soedinenii, 7:956-961 (1977)
	C14	Gvon et al., "Amino-imino tautomerism and intramolecular cyclization of 4, 9-diamino-1, 10-anthraquinone-1-tosylimines" <i>Dokl. Akad. Nauk</i> , 334:465-468 (in Russian with English abstract) (1994)
	C15	Hartley et al., "Characteristics of the interaction of anthrapyrazole anticancer agents with deoxyribonucleic acids: structural requirements for DNA binding, intercalation, and photosensitization", <i>Mol. Pharmacol.</i> 33:265-271 (1988)
	C16	Ivanova et al., "XPS investigation of electronic structure of pyrazolanthrone and its derivatives" <i>Poverkhnost</i> , 4-5:193-201 (1997)
	C17	Jones, W., "The Reaction of 4-Alkyl-3-thiosemicarbazides with B-Haloketones" <i>Heterocycl. Chem.</i> , v. 20(5), pp. 1359-1361 (1983)
	C18	Judson, "The anthropyrazoles: a new class of compounds with clinical activity in breast cancer", <i>Semin. Oncol.</i> 19:687-694 (1992)
	C19	Kawakami et al., "NaH-Mediated One-Pot Cyclocondensation of 6-Nitroquinoline with Aromatic Hydrazone to Form [1,2,4]Triazino[6,5-f]quinolines and/or Pyrazolo[3,4-f]quinolines" <i>Organic Letters</i> , v. 2(3), pp. 413-415 (2000)
	C20	Koltzenburg, M. "Neural Mechanisms of Cutaneous Nociceptive Pain" <i>Clin. J. of Pain</i> 16:S131-S138 (2000)
	C21	Kurvers H.A., "Reflex sympathetic dystrophy: evolution of microcirculatory disturbances in time" <i>Pain</i> 60(3):333-40 (1995)
	C22	Mannion, R.J. and Woolf, C.J., "Pain Mechanisms and Management: A Central Perspective" <i>Clin. J. of Pain</i> 16:S144-S156 (2000)
	C23	Paice, E., "Reflex sympathetic dystrophy" <i>British Medical Journal</i> 310: 1645-1648 (1995)
	C24	Patel et al., "Unsymmetrical cyclic ureas as HIV-1 Protease Inhibitors: Novel Biaryl Indazoles as P2/P2' Substituents" <i>Bioorganic and Medicinal Chemistry Letters</i> , v. 9(22), pp. 3217-3220 (1999)
	C25	Perez, R.S., et al., "J. Pain Symptom Manage" 21(6):511-26 (2001)
	C26	Pfoertner and Foricher "1 H-Indazoles Obtained by Photolysis of 2-Aminophenylketon-0-(ethoxycarbonyl) oximes and of 3,1,4-Benzoxadiazephene-2(1 H)-ones", <i>Helv. Chim. Acta</i> , v. 65(3), pp. 798-806 (1982)
	C27	Schwartzman R.J., "Reflex sympathetic dystrophy" <i>Curr Opin Neurol Neurosurg</i> 6(4):531-6 (1993)
	C28	Schwartzman R.J., "New Treatments for Reflex Sympathetic Dystrophy" <i>N. Engl. J. Med</i> 343(9):654-6 (2000)
	C29	Showalter et al, "Design, Tumor Biology, and Biochemical Pharmacology of Anthropyrazoles" <i>Bioact. Mol. Chapter V1:201-243 (1988)</i>
	C30	Showalter et al., "5-[(Aminoalkyl)amino]-substituted anthra[1,9-cd]pyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation", <i>J. Med. Chem.</i> 27:253-255 (1984)
	C31	Showalter et al., "Anthropyrazole anticancer agents. Synthesis and structure-activity relationships against murine leukemias", <i>J. Med. Chem.</i> 30:121-131 (1987)
	C32	Singh and Shah, "Reactions of 2,2'-ethylene-bis-anthropyrazolone", <i>Indian J. -Chem.</i> 16B:100-102 (1978)
	C33	Sokolyuk et al., "Synthesis and photochemical properties of peri-phenoxy derivatives of 6H-antha[1,9-cd]-6-pyrazolone (pyrazolanthrone)", <i>Zhurnal Organicheskoi Khimii</i> 28:2193-2200 (1992)
	C34	Vasilevsky et al., "Cyclocondensation of activated ortho-chloroaryelacetylenes with hydrazine: a novel route to substituted indazoles" <i>Mendeleev. Commun.</i> , v. 3, pp. 98-99 (1996)
	C35	Walser, et al., "Nucleophilic Displacement of Aromatic Fluorine, Part 1, Synthesis of Benzisoxazoles" <i>J. Heterocycl. Chem.</i> , v. 11(6), pp. 885-888 (1974)
	C36	Wasner G. et al. "Vascular Abnormalities in Acute Reflex Sympathetic Dystrophy (CRPS I)" <i>Arch Neurol</i> 56(5):613-20 (1999)

	C37	Wrzeciono et al., "Part 14: On the behaviour of 5-Chloro-2-Nitroindazole Against Aliphatic and Cyclic Amines" Pharmazie, v. 40(2), pp. 105-108 (1985)
	C38	Wrzeciono et al., "Part 33: 5-Fluoroindazole derivatives" Pharmazie, v. 47(1), pp. 22-24 (1992)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	